Skip to ContentSkip to Navigation
About us Faculty of Law Research Centres of Expertise Global Health Law Groningen Research Centre
Header image Global Health Law Groningen

Results for tag:pharma

Dolutegravir Patent Licences Can Provide Access To All

Date:28 July 2017
Author:GHLG Blog
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential Medicines in response to the recent evidence showing the medicine’s safety, efficacy, and high barrier to resistance. A recent study HIV drug resistance report 2017 launched by the WHO at the IAS2017 shows that in 6 of the 11 countries surveyed in Africa, Asia and Latin America, over 10% of people starting antiretroviral therapy had a strain of HIV that was resistant to some of the most widely used HIV medicines. This is a worrying trend and such levels of resistance demand a review of the treatment practices including switching to more robust ARV regimen.

The Most Common Misunderstanding About Compulsory Licences

Date:01 June 2017
Author:GHLG Blog
The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to bust.

A New Access to Medicines Initiative: Medicines Law & Policy

Date:26 May 2017
Author:GHLG Blog
This week during the WHO’s 70th World Health Assembly, GHLG member Ellen ‘t Hoen announced the launch of the new website, ‘Medicines Law & Policy’, established with colleagues Pascale Boulet and Kaitlin Mara, all experts in intellectual property and access to medicines. ML&P provides expertise in the form of policy and legal analyses, best practice models, and other information to work toward the goal of ensuring the availability of effective, safe, and affordable medicines for all.

Vision for sustainable access to innovative medicines: GHLG & UMCG’s Global Health Unit respond to the OECD

Date:11 May 2017
Author:GHLG Blog
Excessively high prices of innovative medicines threaten patient access and health system sustainability in developing and industrialised countries alike. The Organisation for Economic Co-operation and Development (OECD) has launched a new initiative to facilitate high-level dialogue between stakeholders on access to innovative medicines and the sustainability of prices. On April 30, 2017, members of the GHLG Research Centre and the Global Health Unit in the Dept. of Health Sciences at the University Medical Centre Groningen responded to OECD’s online consultation for sustainable access to innovative medicines. Below are excerpts from our response.